Empowering Oncology Decisions

DiagnoCure is a life sciences company commercializing high-value cancer diagnostic tests and lab services that increase clinician and patient confidence in making critical treatment decisions.

Previstage™ GCC

The Previstage™ GCC Colorectal Cancer Staging Test is now offered by DiagnoCure Oncology Laboratories directly to clinicians.

More on Previstage™ GCC »

Access to DiagnoCure Oncology Laboratories website  »

PCA3 Molecular Marker

The PCA3 test for prostate cancer is available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 in vitro assay.

Special Media Coverage on PCA3 »

More on PCA3 »

External site on PCA3, Ismar Healthcare »

Shc Proteins for Breast, Colon and
other Cancers

On August 2007, DiagnoCure acquired lead proprietary prognostic tests with applications in five tumor types, including breast and colon.

Research on Shc proteins »

Special Announcement

Major clinical study published: GCC (GUCY2C), the strongest predictor of CRC recurrence

Visit our media room
for more information »

INVESTORS

0.86
-0.02
Open: 0.88
$CAN.
Quotes are delayed.

More Investors Info »

 

Previstage™ GCC showcased in the Economic Report (video) »

Latest News

Upcoming Events

September 13 - 15, 2009
2009 Oncology: Clinical Issues & Trends
Washington, DC, United States

October 1 - 3, 2009
ISGIO The 2009 Gastrointestinal Oncology Conference
Washington, DC, United States

October 11 - 14, 2009
CAP ’09–The Pathologists’ Meeting™
Washington, DC, United States

Calendar »